MIRA Pharmaceuticals, Inc. Proceeds from Common Stock Issued
MIRA Pharmaceuticals, Inc. (MIRA) reported Proceeds from Common Stock Issued of $7.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $3.84M, a 700.85% increase year-over-year.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $2.82M.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2025-06-30 was $345.32K.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2025-03-31 was $3.38K.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2025 was $7.01M, a 94.18% increase from fiscal 2024.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2024 was $3.61M, a 53.16% decline from fiscal 2023.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2023 was $7.70M, a 165.30% increase from fiscal 2022.
- MIRA Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2022 was $2.90M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $6.66M derived: sum of 2 quarters · filed 2026-03-31 | $7.00M derived: sum of 3 quarters · filed 2026-08-12 | $7.01M 10-K · filed 2026-03-31 |
| 2025-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.17M derived: sum of 2 quarters · filed 2026-08-12 | $3.17M 10-Q · filed 2025-11-13 | $3.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $345.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $348.70K 10-Q · filed 2026-08-12 | $827.63K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $3.38K 10-Q · filed 2026-05-14 | $482.31K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $478.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.61M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $3.13M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $7.70M 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $7.70M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.19M derived: sum of 2 quarters · filed 2024-04-01 | $2.90M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.62M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $1.72M 10-Q · filed 2023-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |